Evoq Remedies Ltd - 543500 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 3Rd September, 2022
As per attachment03-09-2022
03-09-2022
Evoq Remedies Ltd - 543500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned subject, we hereby submit the confirmation Certificate received from M/s. Accurate Securities & Registry Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of the Securities and Exchange Board India (Depository and Participant) Regulations, 2018 for the Quarter ended on 30th June, 2022. Kindly take the same on your record and oblige us. Thanking You21-07-2022
Evoq Remedies Ltd - 543500 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- BHUMISHTH PATELDesignation :- Managing Director / Whole Time Director19-07-2022
Evoq Remedies Ltd - 543500 - Submission Of Audited Financial Results For The Quarter And Year On 31St March, 2022 Along With Auditor'S Report And Declaration
In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Audited Financial Results for the Quarter and Year ended on 31st March, 2022 along with Auditor's Report and Declaration. Kindly take same on your record and oblige us. Thanking You. Yours Faithfully, For, Evoq Remedies Limited Bhumishth Patel Managing Director DIN: 0251664130-05-2022
Evoq Remedies Ltd - 543500 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 30Th May, 2022
Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e. on 30th May, 2022, at the Registered Office of the Company, which commenced at 12:00 P.M. and concluded at 3:40 P.M. has considered and approved Audited Financial Results for the Quarter and Financial Year ended on 31st March, 2022 along with Auditor's Report and Declaration. Kindly take same on your record and oblige us. Thanking You. Yours Faithfully, For, Evoq Remedies Limited Bhumishth Patel Managing Director DIN: 0251664130-05-2022
Evoq Remedies Ltd - 543500 - Board Meeting Intimation for The Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2022 Along With Auditor'S Report.
Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve the Audited Financial Results of the Company for the Quarter and Year ended on 31st March, 2022 along with Auditor's Report.23-05-2022
Evoq Remedies Ltd - 543500 - Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2022
With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on 31st March, 2022. Kindly take the same on your record and oblige us. Thanking You30-04-2022
Evoq Remedies Ltd - 543500 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayEvoq Remedies Ltd 2CINU24230GJ2010PLC059692 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 10.19 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: TEJ BHARATKUMAR HANJ Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: YOGESH RAJPUT Designation: Chief Financial Officer EmailId: [email protected] Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2022
Evoq Remedies Ltd - 543500 - Compliance Certificate Relating To Share Transfer Facility As Per Regulation 7(3) Of SEBI (LODR) For The Half Year Ended 31St March, 2022
Compliance Certificate relating to Share Transfer Facility as per Regulation 7(3) of SEBI (LODR) for the half year ended 31st March, 202220-04-2022
Evoq Remedies Ltd - 543500 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayEvoq Remedies Ltd 2CINU24230GJ2010PLC059692 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: TEJ HANJ Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: [email protected] Name of the Chief Financial Officer: YOGESH RAJPUT Designation: Chief Financial Officer EmailId: [email protected] Date: 08/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.08-04-2022